medigraphic.com

2020, Number 3

<< Back Next >>

Rev Fac Med UNAM 2020; 63 (3)

Chronic Obstructive Pulmonary Disease (COPD). Bases for the General Practitioner

Martínez LM, Rojas GA, Lázaro PRI, Meza AJE, Ubaldo RL, Ángeles CM

Language: Spanish
References: 28
Page: 28-35
PDF size: 523.65 Kb.


ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a chronic degenerative disease. It is a frequent, preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation. The National Institute of Respiratory Diseases (INER), ranked COPD in 2016 in fourth place in the table of annual morbidity and mortality in Mexico. The prevalence of COPD is directly related to smoking; however, its development is multifactorial.
For its study it is important to know of any prior exposure to risk factors and of any manifestation of the main symptoms. To make a diagnosis, a detailed clinical history, where the largest amount of data is collected from every new possible COPD patient, and a spirometry are essential. Individual pharmacological treatment is necessary due to the great variability among COPD patients. The drugs used in the treatment of COPD reduce the symptoms, the frequency and severity of exacerbations; however, there is no medication that modifies the long-term deterioration of the lung function. Therefore, a basic knowledge of this condition by the medical doctor first contacted, is essential for the suspicion of COPD in its initial stage and thus, offer the patient immediate medical intervention. The objective of the present work is to provide a basic overview of COPD to the general practitioner.


REFERENCES

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Diagnosis, Management and Prevention of COPD 2018. [Acceso 20 de enero de, 2019]. Disponible en: http://goldcopd.org/gold-2017-global-strategy-diagnosis- management-prevention-copd/

  2. McDonald CF, Khor Y. Advances in chronic obstructive pulmonary disease. Intern Med J. 2013;43:854-62.

  3. Raherison C, Girodet PO. Epidemiology of COPD. European Respiratory Review. 2009;18:213-21.

  4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: Systematic review and meta-analysis. European Respiratory Journal. 2006;28:523-32.

  5. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):1-17.

  6. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G et al. Chronic Obstructive Pulmonary Disease in five Latin American cities (the PLATINO Study): a prevalence study. The Lancet. 2005;26:1875-81.

  7. Laniado-Laborín R, Rendón A, Bauerle O. Chronic obstructive pulmonary disease case finding in Mexico in an at-risk population. International Journal of Tuberculosis and Lung Disease. 2011;15(6):818-23.

  8. INER-EPOC, Instituto Nacional de Enfermedades Respiratorias. Disponible en: http://www.iner.salud.gob.mx/ principales/investigacion/-en-tabaquismo-y-epoc.aspx.

  9. Salvi S. Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. Clinics in Chest Medicine. 2014;35(1):17-27.

  10. Rovina N, Koutsoukou A, Koulouris N. Inflammation and immune response in COPD: Where do we stand? Mediators of Inflammation. 2013;1-9.

  11. Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: A look at the evidence. Respiratory Research. 2017;30,18(1):105.

  12. Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest. 2010;138(1):3-6.

  13. Regalado J, Perez-Padilla R, Sansores R, Páramo J, Braurer M, Paré P et al. The effect of biomass Burning on Respiratory Symptoms and Lung Function in Rural Mexico Women. Am J Respir Crit Care Med. 2006;15;174(8):901-5.

  14. Romieu I, Riojas-Rodriguez H, Marrón AT, Schilmann A, Perez-Padilla, Masera O. Improved Biomass Stove Intervention in Rural Mexico. Am J Respir Crit Care Med. 2009;180:649-56.

  15. Dutta A, Roychoudhury S, Chowdhury S, Ray MR. Changes in sputum cytology, airway inflammation and oxidative stress due to chronic inhalation of biomass smoke during cooking in premenopausal rural Indian women. Int J of Hygiene and Environmental Health. 2013;216(3):301-8.

  16. Silva R, Oyarzún M, Olloquequi J. Pathogenic Mechanisms in Chronic Obstructive Pulmonary Disease Due to Biomass Smoke Exposure. Arch Bronconeumol. 2015; 51(6):285-92.

  17. Hansel NN, McCormack MC, Kim V. The Effects of Air Pollution and Temperature on COPD. Journal of Chronic Obstructive Pulmonary Disease. 2016;13(3):372-9.

  18. Kodgule R, Salvi S. Exposure to Biomass Smoke as a Cause for Airway Disease in Women and Children. Current Opinion in Allergy and Clinical Immunology. 2012;12(1):82-90.

  19. Tashkin D P. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opinion on Pharmacotherapy. 2014;15(1): 85-96.

  20. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology. 2016;138(1):16-27.

  21. Ezzati Givi MA, Redegeld F, Folkerts G, Mortaz E. Dendritic Cells in Pathogenesis of COPD. Current Pharmaceutical Design. 2012;18:2329-35.

  22. Shao MXG. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor converting enzyme in human airway epithelial (NCI-H292) cells. AJP: Lung Cellular and Molecular Physiology. 2004;287(2):L420-L7.

  23. Polverino F, Seys LJM, Bracke KR, Owen CA. B cells in chronic obstructive pulmonary disease: moving to center stage. AJP: Lung Cellular and Molecular Physiology. 2016;311(4):L687-L95.

  24. Calle Rubio M, Chacón BM, Rodríguez Hermosa JL. Exacerbation of chronic obstructive pulmonary disease. Arch Bronconeumol. 2010;46:Suppl 7:21-5.

  25. McNicholas WT. Impact of sleep in COPD. Chest 2000; 117:Suppl. 2 48S-53S.

  26. Borsboom GJ, van Pelt W, van Houwelingen HC, van Vianen BG, Schouten JP, Quanjer PH. Diurnal variation in lung function in subgroups from two Dutch populations: consequences for longitudinal analysis. Am J Respir Crit Care Med. 1999;159:1163-71.

  27. García-Río F, Calle M, Burgos F, Casan P, Del Campo F, Galdiz JBet al. Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2013;49(9):388-401.

  28. Schett G, Sloan VS, Stevens RM, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Therapeutic advances in musculoskeletal disease. 2010;2(5):271-8.




2020     |     www.medigraphic.com